Author:
Bhuiyan Sakil,Siddiqui Raheel S,Zirkiyeva Milana,Agladze Mariam,Bashir Tayyaba
Reference15 articles.
1. Global cancer statistics, 2012;Torre LA;CA Cancer J Clin,2015
2. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis;Zhang YL;Oncotarget,2016
3. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial;Mitsudomi T;Lancet Oncol,2010
4. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer. analyses from the phase III, randomized, open-label, ENSURE study 10.1093/annonc/mdv270. https://www.annalsofoncology.org/article/S0923-7534(19)31770-3/fulltext.
5. Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC);Chen G;Ann Oncol,2013
Cited by
4 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献